Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries."Because the industry is a typical' big money' industry, that is, high risk, long cycle and burning money, the nature of biomedicine also determines that it needs mergers and acquisitions in the current environment to become bigger and stronger."For the biomedical industry, Bu Rixin told the reporter of science and technology innovation board Daily that the investment cycle of biomedicine is generally long, and it needs to go through multiple stages from research and development to listing.
Unlike Shenzhen and Anhui, which made good use of "green channel" policies such as debt financing, mergers and acquisitions, and vigorously developed equity-based M&A funds, this time Shanghai directly gave the scale of M&A funds.Since then, after continuing to Shenzhen and Anhui, Shanghai has also made efforts in mergers and acquisitions.Bu Rixin said that only through mergers and acquisitions and accelerating industrial integration can the benign development of the industry be promoted, which is also one of the most effective measures.
For the biomedical industry, Bu Rixin told the reporter of science and technology innovation board Daily that the investment cycle of biomedicine is generally long, and it needs to go through multiple stages from research and development to listing.Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.However, in the field of large chips such as GPU, it has not yet run out of listed companies. It can be seen that Moore Thread, Biwa Technology, Suiyuan Technology, etc. have started the listing counseling process one after another.
Strategy guide
12-14
Strategy guide
Strategy guide